A phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F)

Shah, Mazhar Ali; Kortmansky, Jeremy; Gönen, Mithat; Tse, Archie; Lefkowitz, Robert A.; Kelsen, David P.; Colevas, Dimitrios; Winkelman, J.; Shi, Yi; Schwartz, Gary N.

doi:10.1200/jco.2004.22.90140.4027

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A phase I study evaluated irinotecan and cisplatin followed by flavopiridol in patients with advanced cancer. Two of three EC patients achieved a PR 43 . A phase I study of weekly docetaxel followed by flavopiridol did not show a response in EC patients 44 .…”

Section: Targeting the Cell Cyclementioning

confidence: 87%

“…Two of three EC patients achieved a PR. 43 A phase I study of weekly docetaxel followed by flavopiridol did not show a response in EC patients. 44 Two trials evaluated the combination of paclitaxel followed by flavopiridol.…”

Section: Targeting the Cell Cyclementioning

confidence: 98%

“…Of the three single‐agent flavopiridol phase I trials that included 172 patients, none of five EC patients responded 40–42 . Flavopiridol has also been evaluated in combination with chemotherapeutic agents 43–47 . A phase I study evaluated irinotecan and cisplatin followed by flavopiridol in patients with advanced cancer.…”

Section: Targeting the Cell Cyclementioning

confidence: 99%

“…[40][41][42] Flavopiridol has also been evaluated in combination with chemotherapeutic agents. [43][44][45][46][47] A phase I study evaluated irinotecan and cisplatin followed by flavopiridol in patients with advanced cancer. Two of three EC patients achieved a PR.…”

Section: Targeting the Cell Cyclementioning

confidence: 99%

See 3 more Smart Citations

Novel targeted therapies for advanced esophageal cancer

Lin¹,

Papadopoulos

2007

Diseases of the Esophagus

View full text Add to dashboard Cite

Esophageal cancer is highly aggressive and is the sixth leading cause of cancer death worldwide. Recent advances in multimodality chemoradiotherapy and surgery has improved survival in patients with loco-regional disease, but most patients with advanced stage esophageal cancer have a poor prognosis. Elucidation of the processes involved in esophageal carcinogenesis has identified a number of promising novel targets for therapy. This review focuses on the current status of targeted therapies with potential application to the treatment of advanced esophageal and gastroesophageal junction cancer. The future challenge is to confirm the efficacy of these targeted agents in appropriately selected esophageal cancer patients, and successfully integrate these agents into effective therapies for all stages and subtypes of disease.

show abstract

Section: Targeting the Cell Cyclementioning

confidence: 87%

Section: Targeting the Cell Cyclementioning

confidence: 98%

Section: Targeting the Cell Cyclementioning

confidence: 99%

Section: Targeting the Cell Cyclementioning

confidence: 99%

See 2 more Smart Citations

Novel targeted therapies for advanced esophageal cancer

Lin¹,

Papadopoulos

2007

Diseases of the Esophagus

View full text Add to dashboard Cite

show abstract

A Review of the Genomics of Gastric Cancer

Hamilton

Meltzer

2006

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

Targeting the Cell Cycle: A New Approach to Cancer Therapy

Schwartz

Shah

2005

JCO

723

539

View full text Add to dashboard Cite

The cell cycle represents a series of tightly integrated events that allow the cell to grow and proliferate. Critical parts of the cell cycle machinery are the cyclin-dependent kinases (CDKs), which, when activated, provide a means for the cell to move from one phase of the cell cycle to the next. The CDKs are regulated positively by cyclins and regulated negatively by naturally occurring CDK inhibitors (CDKIs). Cancer represents a dysregulation of the cell cycle such that cells that overexpress cyclins or do not express the CDKIs continue to undergo unregulated cell growth. The cell cycle also serves to protect the cell from DNA damage. Thus, cell cycle arrest, in fact, represents a survival mechanism that provides the tumor cell the opportunity to repair its own damaged DNA. Thus, abrogation of cell cycle checkpoints, before DNA repair is complete, can activate the apoptotic cascade, leading to cell death. Now in clinical trials are a series of targeted agents that directly inhibit the CDKs, inhibit unrestricted cell growth, and induce growth arrest. Recent attention has also focused on these drugs as inhibitors of transcription. In addition, there are now agents that abrogate the cell cycle checkpoints at critical time points that make the tumor cell susceptible to apoptosis. An understanding of the cell cycle is critical to understanding how best to clinically develop these agents, both as single agents and in combination with chemotherapy.

show abstract

A phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F)

Cited by 3 publications

References 0 publications

Novel targeted therapies for advanced esophageal cancer

Novel targeted therapies for advanced esophageal cancer

A Review of the Genomics of Gastric Cancer

Targeting the Cell Cycle: A New Approach to Cancer Therapy

Contact Info

Product

Resources

About